Veeva Systems Inc Class A (VEEV) Fair Value & Analysis
Healthcare · US · Market cap $30.9B · ISIN US9224751084
What is Veeva Systems Inc Class A really worth?
Veeva Systems Inc Class A
VEEV · US
A solid business, but trading 211% above our fair value of $91.49.
Strengths
Risks
Fair value as of: Aug 29, 2026
From 26 valuation models · updated 7 days ago
Share price +34.2% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A high-quality business (quality 72/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case ($138.02). The favourable scenario is already priced in.
- A fairly wide model range ($70.65 to $138.02) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 29, 2026.
How to read this chart
60‑month range $151.10 – $341.00 · fair‑value band $70.65 – $138.02 · the $284.38 price screens above the $91.49 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 29, 2026.
Analysis
Veeva Systems Inc Class A (VEEV) currently trades at $284.38, while our model-based Fair Value estimate is $91.49, implying the stock looks roughly 210.8% overvalued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of $213.32 per share, and 0 of the 26 models we run sit above the $284.38 price. Bear case: the Asset-Based group reads lowest at $29.76, and 26 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Veeva Systems Inc Class A generated revenue of $3.3B at a net margin of 28.4%. Revenue grew 16.3% year over year. It earns a return on equity of 13.9%. The balance sheet holds a net cash position of $1.3B. Fundamentals as of Aug 29, 2026
Our scenario range runs from $70.65 (bear case) to $138.02 (bull case); at $284.38, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 8% below its 52-week high and 92% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −64% fair-value upside, at −68%, VEEV screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2026 figures, and about 7 months have passed since. In that time the company retained roughly $3.35 per share, which is 3.7 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: DCF Models ($213.32) versus Dividend Discount ($0.3700). Highest evidence: FCF DCF (76).
Notify me when VEEV reaches fair value
Put VEEV on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 29, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 72 · Market factors (momentum, volatility) 61
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America.
Full company description
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides Veeva Data Cloud, such as Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics. In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials; Veeva Safety, which unifies systems and processes; Veeva RIM that provides regulatory information management capabilities, as well as Veeva Quality Cloud, which is used by the life sciences and consumer products industries; and Veeva Business Consulting services. Further, it provides professional and support services, including implementation and deployment planning, and project management; requirements analysis, solution design, and configuration; systems environment management and deployment; services focused on advancing or transforming business and operating processes; technical consulting services on data migration and systems integrations; training; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Veeva Systems Inc Class A reported revenue of $3.2B in FY2026 versus $1.9B in FY2022, a compound +14.6%/yr. Reported net income was $909M in FY2026, compounding +20.8%/yr from FY2022.
of which total revenue +23.2 % · buybacks/dilution −1.4 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
VEEV screens 211% overvalued. Compare with Pro Medicus Limited →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Jim Cramer Breaks Down the Enterprise Software Rebound for Salesforce (CRM) and Veeva (VEEV)
- Veeva to Present at Upcoming Investor Conferences
Peer Group
Health Information Services · 128 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 46/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 29, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Pro Medicus Limited PME | A$183.71 | A$23.74 | −87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | −64% |
| HealthEquity, Inc HQY | $104.27 | $56.63 | −46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | −72% |
| 10x Genomics, Inc TXG | $55.63 | $17.18 | −69% |
| Waystar Holding WAY | $25.76 | $12.86 | −50% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | −87% |
| Doximity, Inc DOCS | $24.74 | $25.91 | +5% |
| Privia Health Group PRVA | $21.07 | $5.26 | −75% |
| IKS IKS | ₹1,785 | ₹830.74 | −53% |
Compare Veeva Systems Inc Class A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Veeva Systems Inc Class A (VEEV) overvalued or undervalued?
What is the fair value of VEEV?
What is the quality score of VEEV?
What is the revenue of Veeva Systems Inc Class A (VEEV)?
What is the net profit margin of VEEV?
Does Veeva Systems Inc Class A pay a dividend?
Watch Veeva Systems Inc Class A in the live analysis
One click puts Veeva Systems Inc Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.